CD47: the next checkpoint target for cancer immunotherapy
| Autor: | Ridong Feng, Hai Zhao, Jianguo Xu, Chongyang Shen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_treatment
CD47 Antigen 03 medical and health sciences 0302 clinical medicine Immune system Cancer immunotherapy Phagocytosis Neoplasms Medicine Humans business.industry CD47 Hematology Immunotherapy medicine.disease Immune checkpoint Blockade Lymphoma Oncology 030220 oncology & carcinogenesis Cancer research Rituximab business 030215 immunology medicine.drug |
| Zdroj: | Critical reviews in oncology/hematology. 152 |
| ISSN: | 1879-0461 |
| Popis: | Cancer immunotherapy using checkpoint blockade has brought about a paradigm shift in the treatment of advanced-stage cancers. Unfortunately, not all patients benefit from these therapies, paving the way for other immune checkpoints to be targeted. CD47, a 'marker-of-self' protein that is overexpressed broadly across tumor types, is emerging as a novel potent macrophage immune checkpoint for cancer immunotherapy. Recently, CD47 blockade by Hu5F9-G4 has shown promise combined with Rituximab in non-Hodgkin's lymphoma. Here we review the complex structure and various physiological functions of CD47 and their implications in cancer biology. Further, this review considers future directions and challenges in advancing this promising target platform to widespread therapeutic use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect